Research programme: antibody therapeutics - Sevion Therapeutics

Drug Profile

Research programme: antibody therapeutics - Sevion Therapeutics

Alternative Names: FB 001; FB 002; FB 003; FB 004; G protein-coupled receptor modulators - Sevion Therapeutics; Ion channel antagonists - Sevion Therapeutics; SVN-001; SVN-002

Latest Information Update: 01 Dec 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Fabrus
  • Developer Sevion Therapeutics
  • Class Antibodies
  • Mechanism of Action Angiogenesis modulating agents; G protein-coupled receptor modulators; Immunomodulators; Ion channel antagonists; Kv1.3 potassium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer; Inflammation
  • Research Pain

Most Recent Events

  • 09 Sep 2014 Senesco Technologies changes name to Sevion Therapeutics
  • 25 Jun 2014 Preclinical trials in Inflammation in USA (Parenteral)
  • 27 May 2014 Research programme: antibody therapeutics - Fabrus is available for licensing as of 27 May 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top